Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2009 1
2010 1
2011 10
2012 7
2013 9
2014 11
2015 13
2016 12
2017 11
2018 12
2019 13
2020 18
2021 19
2022 23
2023 18
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Results by year

Filters applied: . Clear all
Page 1
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis.
Ipek Y, Kilic B, Gunay UB, Eskazan AE. Ipek Y, et al. Among authors: eskazan ae. Expert Opin Investig Drugs. 2023 Jul-Dec;32(10):931-940. doi: 10.1080/13543784.2023.2269078. Epub 2023 Nov 6. Expert Opin Investig Drugs. 2023. PMID: 37811861 Review.
Dasatinib-induced pulmonary arterial hypertension.
Özgür Yurttaş N, Eşkazan AE. Özgür Yurttaş N, et al. Among authors: eskazan ae. Br J Clin Pharmacol. 2018 May;84(5):835-845. doi: 10.1111/bcp.13508. Epub 2018 Mar 6. Br J Clin Pharmacol. 2018. PMID: 29334406 Free PMC article. Review.
Postoperative thrombotic thrombocytopenic purpura.
Eskazan AE, Buyuktas D, Soysal T. Eskazan AE, et al. Surg Today. 2015 Jan;45(1):8-16. doi: 10.1007/s00595-013-0823-y. Epub 2013 Dec 29. Surg Today. 2015. PMID: 24374368 Review.
Olverembatinib in chronic myeloid leukemia.
Öziskender R, Eşkazan AE. Öziskender R, et al. Among authors: eskazan ae. Drugs Today (Barc). 2022 Nov;58(11):531-538. doi: 10.1358/dot.2022.58.11.3441854. Drugs Today (Barc). 2022. PMID: 36422514
Rare and Aggressive Disease: Challenge.
Sönmez Ö, Küçükyurt S, Önenerk Men AM, Demiröz AS, Eşkazan AE. Sönmez Ö, et al. Among authors: eskazan ae. Am J Dermatopathol. 2022 Aug 1;44(8):e84-e85. doi: 10.1097/DAD.0000000000002215. Am J Dermatopathol. 2022. PMID: 35830704 No abstract available.
Novel therapeutic approaches in chronic myeloid leukemia.
Özgür Yurttaş N, Eşkazan AE. Özgür Yurttaş N, et al. Among authors: eskazan ae. Leuk Res. 2020 Apr;91:106337. doi: 10.1016/j.leukres.2020.106337. Epub 2020 Feb 25. Leuk Res. 2020. PMID: 32200189 Review.
Upregulation of SPINK2 in acute myeloid leukemia.
Gezer S, Emrence Z, Elverdi T, Ar MC, Salman Yaylaz B, Paçal F, Ünüvar A, Sarıman M, Eşkazan AE, Karaman S, Salihoğlu A, Karakaş Z, Abacı N, Sırma-Ekmekci S. Gezer S, et al. Among authors: eskazan ae. Adv Lab Med. 2023 Feb 20;4(1):92-104. doi: 10.1515/almed-2022-0047. eCollection 2023 Apr. Adv Lab Med. 2023. PMID: 37359898 Free PMC article. Review.
Editorial: Advances in the treatment of chronic myeloid leukemia.
Eşkazan AE, Kok CH, Yeung D, Dalal J, Tiribelli M. Eşkazan AE, et al. Front Oncol. 2023 Mar 9;13:1166588. doi: 10.3389/fonc.2023.1166588. eCollection 2023. Front Oncol. 2023. PMID: 36969003 Free PMC article. No abstract available.
160 results